Walter Alexander

Among patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.

In the “real world” NABUCCO trial, results with nab-paclitaxel were consistent with those reported in the pivotal trial among patients with metastatic breast cancer who are ineligible to receive anthracycline therapy.

Toxicities associated with capecitabine may be better managed by dose reductions and/or a week-on/week-off (WOWO) dosing schedule among patients aged 70 years or older with metastatic breast cancer.